These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22683223)

  • 1. 6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.
    Yuan Y; Stevens DL; Braithwaite A; Scoggins KL; Bilsky EJ; Akbarali HI; Dewey WL; Zhang Y
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4731-4. PubMed ID: 22683223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.
    Yuan Y; Li G; He H; Stevens DL; Kozak P; Scoggins KL; Mitra P; Gerk PM; Selley DE; Dewey WL; Zhang Y
    ACS Chem Neurosci; 2011 Jul; 2(7):346-51. PubMed ID: 22816021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.
    Williams DA; Zheng Y; David BG; Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Selley DE; Dewey WL; Akbarali HI; Zhang Y
    ACS Chem Neurosci; 2016 Aug; 7(8):1120-9. PubMed ID: 27269866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
    Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
    J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.
    Zheng Y; Obeng S; Wang H; Stevens DL; Komla E; Selley DE; Dewey WL; Akbarali HI; Zhang Y
    ACS Chem Neurosci; 2018 Dec; 9(12):3028-3037. PubMed ID: 30001114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.
    Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Zhang F; Stevens DL; Beletskaya IO; Scoggins KL; Zhang Z; Gerk PM; Selley DE; Akbarali HI; Dewey WL; Zhang Y
    J Med Chem; 2012 Nov; 55(22):10118-29. PubMed ID: 23116124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation Treatment.
    Huang B; Li M; Klongkumnuankarn P; Mendez RE; Gillespie JC; Stevens DL; Dewey WL; Selley DE; Zhang Y
    J Med Chem; 2022 Mar; 65(6):4991-5003. PubMed ID: 35255683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.
    Zhang Y; Williams DA; Zaidi SA; Yuan Y; Braithwaite A; Bilsky EJ; Dewey WL; Akbarali HI; Streicher JM; Selley DE
    ACS Chem Neurosci; 2016 Mar; 7(3):297-304. PubMed ID: 26716358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.
    Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y
    Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
    Wang D; Raehal KM; Bilsky EJ; Sadée W
    J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
    Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
    J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy.
    Sirohi S; Kumar P; Yoburn BC
    J Pharmacol Exp Ther; 2007 Nov; 323(2):701-7. PubMed ID: 17698975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.
    Yuan Y; Zaidi SA; Elbegdorj O; Aschenbach LC; Li G; Stevens DL; Scoggins KL; Dewey WL; Selley DE; Zhang Y
    J Med Chem; 2013 Nov; 56(22):9156-69. PubMed ID: 24144240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
    Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
    Divin MF; Bradbury FA; Carroll FI; Traynor JR
    Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.
    Mitra P; Venitz J; Yuan Y; Zhang Y; Gerk PM
    Drug Metab Dispos; 2011 Sep; 39(9):1589-96. PubMed ID: 21685245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the morphine-induced inhibition of small and large intestinal transit: Involvement of central and peripheral μ-opioid receptors in mice.
    Matsumoto K; Umemoto H; Mori T; Akatsu R; Saito S; Tashima K; Shibasaki M; Kato S; Suzuki T; Horie S
    Eur J Pharmacol; 2016 Jan; 771():220-8. PubMed ID: 26712376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey.
    Ko MC; Divin MF; Lee H; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2006 Feb; 316(2):772-9. PubMed ID: 16258020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
    Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
    Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone.
    Porter SJ; Somogyi AA; White JM
    Addict Biol; 2002 Apr; 7(2):219-25. PubMed ID: 12006217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.